>latest-news

Palisade Bio Secures Canadian Patent For Composition Of Its Lead Product Candidate PALI-2108

Palisade Bio secures a new Canadian patent for PALI-2108, its gut-targeted PDE4 inhibitor for Crohn’s disease and ulcerative colitis, extending protection through 2041.

Breaking News

  • Oct 14, 2025

  • Simantini Singh Deo

Palisade Bio Secures Canadian Patent For Composition Of Its Lead Product Candidate PALI-2108

Palisade Bio, Inc., a clinical-stage biopharmaceutical company focused on developing precision therapies for autoimmune, inflammatory, and fibrotic diseases, has announced that the Canadian Intellectual Property Office (CIPO) has granted patent number 3,174,137, titled “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” The newly granted patent provides composition-of-matter protection for PALI-2108, the company’s first-in-class, orally administered, ileocolonic-targeted PDE4 B/D inhibitor currently in development for the treatment of fibrotic small bowel Crohn’s disease (FSCD) and ulcerative colitis (UC).


The patent secures protection for PALI-2108 through May 28, 2041, representing a key addition to Palisade Bio’s growing global intellectual property portfolio. PALI-2108’s innovative design features a galactose-derived sugar moiety that prevents significant absorption in the upper gastrointestinal tract. The compound is converted into its active form by the enzyme β-glucuronidase, which is produced by colonic bacteria. This mechanism enables localized bioactivation, ensuring colon-specific drug delivery with reduced systemic exposure—an effect confirmed in a preclinical tissue distribution study.


Commenting on the milestone, J.D. Finley, Chief Executive Officer of Palisade Bio, said, “We remain deeply committed to expanding and strengthening our intellectual property portfolio around PALI-2108 as we advance its clinical development. The granting of this patent marks an important step in reinforcing the value of our innovative platform. Our team continues to make strong progress toward key clinical milestones, and we look forward to unlocking the full therapeutic potential of PALI-2108 for patients with FSCD and UC.”


Palisade Bio is currently advancing PALI-2108 in a Phase 1b clinical trial for FSCD, with patient dosing expected to begin in the second half of 2025 and topline data anticipated in the first quarter of 2026. Data from this study, combined with results from the company’s completed Phase 1a/1b trials in ulcerative colitis, will support a planned Phase 2 Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA) in the first half of 2026.


The newly granted Canadian patent strengthens Palisade Bio’s proprietary position for PALI-2108 and underscores the company’s ongoing efforts to develop next-generation targeted therapies that address the complex mechanisms driving autoimmune and inflammatory diseases.

Ad
Advertisement